Biocytogen -H (2315.HK) traded up 0.68 % during a 24 hours period ending at 05:11 PM Central Europe on Monday 26th. One Biocytogen -H stock can currently be bought for about HKD 39.98 on popular exchanges. Current supply of Biocytogen -H stocks is 898.1 mn. Biocytogen -H has a current market capitalization of HKD 37.3 bn and approximately HKD 125.2 mn worth of Biocytogen -H was traded on exchanges in the last 24 hours. Since last month end, Biocytogen -H has traded -38.65 % down. Simple moving average of last 200 days is at HKD 52.77. The highest price of past 52 weeks was recorded at HKD 80.65 on 10/06/2026. 52 weeks low was at HKD 23.94 on 10/30/2025.
Here is how related stocks have performed in the past 24 hours:
Shaanxi Energy Investment (001286.SZ) traded flat 0 % and now trades at CNY 10.21. Current market capitalisation for Shaanxi Energy Investment is CNY 37.9 bn.
Guobo Electronics (688375.SS) traded flat 0 % and now trades at CNY 62.27. Guobo Electronics has a market capitalisation of CNY 37.8 bn.
Asr Microelectronics Lt (688220.SS) traded flat 0 % and now trades at CNY 88.63. Current market capitalisation for Asr Microelectronics Lt is CNY 37.3 bn.
China Greatwall (000066.SZ) traded flat 0 % and now trades at CNY 11.74. China Greatwall has a market capitalisation of CNY 38 bn. China Greatwall has a current price to earnings ratio of 322.52.
Shanghai Fosun Pharmaceuti-h (2196.HK) traded up 1.35 % and now trades at HKD 16.66. Current market capitalisation for Shanghai Fosun Pharmaceuti-h is HKD 44 bn. Current price/earnings ratio for Shanghai Fosun Pharmaceuti-h is 11.21. Shanghai Fosun Pharmaceutical (Group) announced its most recent quarterly results at a three‑month financial conference. Analysts expected a modest rise in earnings per share and revenue compared to the previous year, with the company’s performance seen as solid but not transformative. Forecasts for the full fiscal year projected continued growth in both profit and sales, reflecting a positive trajectory for the group. The disclosure also highlighted forthcoming industry data releases and regulatory changes affecting the broader market. Overall, the company’s update reinforced its steady position within the pharmaceutical sector, indicating incremental gains rather than dramatic shifts in financial performance.
About Biocytogen -H
Biocytogen Pharmaceuticals Beijing Co., Ltd. is a biopharmaceutical and revenue-generating preclinical research services company operating in China’s health care sector. The company produces various biological agents such as monoglobulins, monoclonal antibodies, recombinant humanized antibodies, and others. Biocytogen Pharmaceuticals Beijing offers drug development, therapeutic antibody discovery and development, and other services. You can find more information about the company and its activities on their website, www.biocytogen.com.cn , and they are listed on the Hong Kong Stock Exchange.